Here’s my rough “back of the envelope” valuation for IHL-42X assuming a drug is created.
Resmed on track to produce A$5b revenue for the year and this is estimated to be 55% of global CPAP revenue. So global revenue is therefore approx $9b.
Could an OSA drug disrupt 5% of this market? Absolutely.
That would be $450m per annum. Even on a 10x revenue basis that’s a market cap exceeding $4.5b.
10% disruption would be $9b valuation.
And there’s no value assumed for all the other promising clinical programs.
Now I’m sure you could shoot some holes in the numbers but I think that’s actually being really conservative.
The point is the prize is significant and watching the daily price volatility often makes you lose focus on what this management team is on track to achieve.
- Forums
- ASX - By Stock
- IHL
- IHL - INCANNEX - HOLDERS RESEARCH
IHL - INCANNEX - HOLDERS RESEARCH, page-449
-
-
- There are more pages in this discussion • 780 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online